Authors: K. Khalighi, G. Cheng, S. Mirabbasi, B. Khalighi, Y. Wu and W. Fan
Arachidonic acids are metabolized by cytochromes P450 (CYP450) to epoxyeicosatrienoic acids (EETs). EETs have many cardiovascular protective effects such as vasodilation, anti-hypertension, anti-inflammation, lipid-lowering effects, and favorable effects on glucose homeostasis. This study aimed to investigate whether gene poly.. Read More»
Authors: M.Q. Lin, J. Zhang, H.F. Qiu, X.B. Xie and H.T. Song
This study was designed to analyze the influence of polymorphisms in CYP2C9, VKORC1, CYP4F2, GGCX, and EPHX1 genes on the optimal warfarin dosage in patients who have undergone artificial heart valve replacement and establish an algorithm for use by physicians in Southeast China to predict each patient’s optimal steady-s.. Read More»
Authors: J.A. Nastasi-Catanese1, J.R. Padilla-Guti�©rrez2, Y. Valle2, F. Ortega-Guti�©rrez3, M.P. Gallegos-Arreola4 and L.E. Figuera5,6
Oral anticoagulants of the coumarin type have an inconveniently narrow therapeutic window, making their use difficult. In Mexico, genetic variables that participate in the heterogeneity of the therapeutic response remain poorly investigated. With the focus on warfarin, extensive pharmacogenomic studies have been performed, including those on the CYP450 fa.. Read More»
Authors: M. Zhang, Y. Yang, G. Zhao, X. Di, L. Xu, N. Jiang, J. Xu and X. Xu
The aim of this study was to investigate the effect of the CYP2C9*3 (CYP2C9 1075 A>C) polymorphism on meloxicam pharmacokinetics in a Chinese population. Twenty-four healthy volunteers were enrolled in this study. The pyrosequencing technique was used to identify polymorphisms of CYP2C9. The concentration of meloxicam in pl.. Read More»
Authors: Z.F. Yang, H.W. Cui, T. Hasi, S.Q. Jia, M.L. Gong and X.L. Su
We examined the distribution of major allelic variants of CYP2C9 and CYP2C19 in the Mongolian population of China and compared it with that of other populations. The polymorphisms of CYP2C9 (including the CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles) and CYP2C19 (including the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles) were analyz.. Read More»
Authors: P. Scibona, M.A. Redal, L.G. Garfi, J. Arbelbide, P.F. Argibay and W.H. Belloso
Dicumarinic oral anticoagulants have a narrow therapeutic range and a great individual variability in response, which makes calculation of the correct dose difficult and critical. Genetic factors involved in this variability include polymorphisms of genes that encode the metabolic enzyme CYP2C9 and the target enzyme vitamin K .. Read More»